|
|
|
By Martin Dahl, Ph.D., AnaptysBio, Inc. | Drawing from experiences with ongoing work at AnaptysBio, Inc., senior VP of research Martin Dahl, Ph.D., shares three considerations when developing immune cell modulators to treat and modify inflammatory disease. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|